NCT03126422

Brief Summary

The investigators aimed to investigate the effects of pretreatment with different doses of dexmedetomidine on the cough caused by fentanyl during anesthetic induction. Patients undergoing elective surgeries under general anesthesia will be randomly allocated to 4 groups (n = 60, each group). Dexmedetomidine 0, 0.03, 0.06, and 0.09 μg/kg/min will be pump-administered in 10 mins to groups I, II, III, and IV, respectively, followed by the induction of general anesthesia with intravenous fentanyl 4 μg/kg. The incidences and severity of cough that occurred within 2 min after the injection of fentanyl will be recorded, and the incidences of cardiovascular adverse events that occurred between the administration of the dexmedetomidine infusion and 2 min after tracheal intubation will be recorded.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
240

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started May 2017

Shorter than P25 for phase_1

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 14, 2017

Completed
10 days until next milestone

First Posted

Study publicly available on registry

April 24, 2017

Completed
7 days until next milestone

Study Start

First participant enrolled

May 1, 2017

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2017

Completed
Last Updated

July 5, 2017

Status Verified

July 1, 2017

Enrollment Period

4 months

First QC Date

April 14, 2017

Last Update Submit

July 2, 2017

Conditions

Outcome Measures

Primary Outcomes (4)

  • The incidence of cough

    Yes or No

    After the infusion of dexmedetomidine up to 10 minutes

  • The time of cough

    After the infusion of dexmedetomidine up to 10 minutes

    After the infusion of dexmedetomidine up to 10 minutes

  • The severity of cough

    minor, moderate, severe

    After the infusion of dexmedetomidine up to 10 minutes

  • The occurence of adverse effects of dexmedetomidine

    bradycardia, hypotension, hypertension

    After the infusion of dexmedetomidine up to 10 minutes

Study Arms (4)

Dexmedetomidine 0 μg/kg/min

EXPERIMENTAL
Drug: Dexmedetomidine

Dexmedetomidine 0.03 μg/kg/min

EXPERIMENTAL
Drug: Dexmedetomidine

Dexmedetomidine 0.06 μg/kg/min

EXPERIMENTAL
Drug: Dexmedetomidine

Dexmedetomidine 0.09 μg/kg/min

EXPERIMENTAL
Drug: Dexmedetomidine

Interventions

Pretreatment of different doses of dexmedetomidine

Dexmedetomidine 0 μg/kg/minDexmedetomidine 0.03 μg/kg/minDexmedetomidine 0.06 μg/kg/minDexmedetomidine 0.09 μg/kg/min

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients undergoing elective surgeries under general anesthesia.

You may not qualify if:

  • Patients with contraindications of dexmedetomidine.
  • Patients younger than 18 years old and older than 65 years old.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

the Affiliated Hospital of Yangzhou University, Yangzhou University

Yangzhou, Jiangsu, 225012, China

RECRUITING

Related Publications (1)

  • Zhou W, Zhang D, Tian S, Yang Y, Xing Z, Ma R, Zhou T, Bao T, Sun J, Zhang Z. Optimal dose of pretreated-dexmedetomidine in fentanyl-induced cough suppression: a prospective randomized controlled trial. BMC Anesthesiol. 2019 Jun 1;19(1):89. doi: 10.1186/s12871-019-0765-z.

MeSH Terms

Interventions

Dexmedetomidine

Intervention Hierarchy (Ancestors)

ImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Central Study Contacts

Zhuan Zhang, Professor

CONTACT

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director

Study Record Dates

First Submitted

April 14, 2017

First Posted

April 24, 2017

Study Start

May 1, 2017

Primary Completion

September 1, 2017

Study Completion

September 1, 2017

Last Updated

July 5, 2017

Record last verified: 2017-07

Locations